Abstract

In June 2021, Broekhoff et al published a cost-effectiveness model of onasemnogene abeparvovec, a single-dose gene replacement therapy, for spinal muscular atrophy (SMA) type 1. We would like to provide feedback on the relapse scenarios, which we consider implausible, even as hypothetical scenarios, and contradictive to published clinical evidence.